摘要
目的探讨瑞格列奈治疗初诊Ⅱ型糖尿病的降糖效果及对β细胞功能的影响。方法选择初诊Ⅱ型糖尿病患者64例,按入院的先后顺序随机分为观察组与对照组各32例。观察组给予瑞格列奈1mg,每日3次,对照组给予格列吡唪5mg,每天1次。两组均采用甘精胰岛素作为基础治疗,起始剂量为0.1U/kg.d,根据FGP水平调整使用剂量,使FGP水平控制在5～6mmol/L,2周复查1次,随访3个月。结果两组治疗3个月后,餐前及餐后的血糖及HbA1c均较治疗前明显下降,组间比较差异有统计学意义(P<0.05)。结论瑞格列奈在治疗初诊Ⅱ型糖尿病中控制餐后血糖、HbA1c,改善β细胞功能较格列吡唪更好,值得临床推广应用。
Objective To explore the hypoglycemic effect and β-cell function of repaglinide in treatment of newly diagnosed type 2 diabetes. Methods By order of admission, 64 patients with rmwly diagnosed type 2 diabetes has randomly divided into observation group and control group （n= 32）. The observation group was given repaglinide （ling, tid） and the control group was given pyrylium （5mg qd）. The two groups were insulin glargine as a basis for treatment. The starting dose for 0. 1U/kg d FGP level adjustment of dose, FGP level of control in 5-6mmol/L, 2 weeks review time. Results After 3 months of treatment, a drop in fasting and postprandial blood glucose and HbAte and review time were apparent. The difference was statistically significance between groups（P〈0.05）. Conclusion Repaglinide is better than pyrylium on controlling postprandial blood glucose of HbAlc and improving β-ce11 function in treatment of newly diag- nosed type 2 diabetes.
出处
《西部医学》
2012年第11期2092-2093,共2页
Medical Journal of West China
